
|Articles|May 21, 2009
Predicting diabetic retinopathy progression
A diabetic retinopathy (DR) progression biomarker software has been developed with the research institute AIBILI (Association for Biomedical Research and Innovation in Light and Image) and Critical Health. The RetmarkerDR is able to calculate and provide important ratios regarding Microaneurysm Turnover (formation and disappearance rates) which are key indicators of progression of retinal diseases like Diabetic Retinopathy.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Macular laser picks up speed: The technology accelerating retinal therapies
2
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
3
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
4
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
5













































